This study will be useful to investigate PD-L1 expression as a biomarker for inclusion in future immunotherapy clinical trials in OC as well as other cancers, to evaluate its utility to select for patients who can respond better to immunotherapeutic regimens. The gene discussed is CD274; the disease is cancer.